Sunitinib, a multiple receptor tyrosine kinase inhibitor, is used in the treatment of renal cell carcinoma and gastrointestinal stromal tumors. Sunitinib-induced thyroid dysfunction has been reported; however, autoimmunity has not been thoroughly described during sunitinib treatment. In this report, we present a 57-year-old man with metastatic RCC who had transient subclinical hyperthyroidism and hypothyroidism during sunitinib therapy. He also developed anti nuclear antibody (speckled pattern) and antidouble stranded DNA positivity.